The in vitro antibacterial activity of DQ-2556, a new semisynthetic cephalosporin, was compared with that of ceftazidime and cefotaxime. The activity of DQ-2556 against members of the family Enterobacteriaceae was roughly comparable to that of cefotaxime. Against Pseudomonas aeruginosa, DQ-2556 was slightly less active than ceftazidime. DQ-2556 was more active than the reference cephalosporins against staphylococci. Haemophilus influenzae and Neisseria gonorrhoeae were also highly susceptible to DQ-2556. 
During the past decade, the development of new cephalosporins has aimed at increasing r-lactamase stability, broadening the spectrum of activity, and enhancing activity against gram-negative pathogens. The new cephalosporins, however, are less active than older compounds against staphylococci and are moderately active against Pseudomonas aeruginosa (3, 5, 6) . Moreover, the clinical usefulness of these enzyme-stable cephalosporins is sometimes limited, owing to the emergence of resistance of certain nonfastidious gram-negative bacteria, such as Serratia, Enterobacter, and Citrobacter spp., during therapy (8) . Thus, there is still a pressing need for effective antibiotics against both grampositive and gram-negative pathogens. Newer cephalosporins, including HR810 (2), BMY-28142 (1), and DN-9550 (10), are being developed based on this concept. DQ-2556 ( Fig. 1) CFU/ml and a subculture volume of 10 pl. The MBC was recorded as the lowest compound concentration that produced 99.9% or greater killing of the initial inoculum (7) .
The overall activity of DQ-2556 compared with that of ceftazidime and cefotaxime is shown in Table 1 . The MICs of DQ-2556 at which 90% of the isolates were inhibited (MIC90s) were 1.56, 3.13, and 1.56 ,ug/ml against Staphylococcus aureus, Staphylococcus epidermidis, and Staphylo-* Corresponding author. coccus saprophyticus, respectively. At this level, DQ-2556 was more active than cefotaxime and ceftazidime. Against Streptococcus pneumoniae and Streptococcus pyogenes, DQ-2556 exhibited excellent activity, as did cefotaxime: all the isolates were inhibited by 0.10 pLg/ml. DQ-2556, as well as the reference cephalosporins, showed poor activity against Streptococcus faecalis.
DQ-2556 was highly active against Escherichia coli, Klebsiella spp., Proteus mirabilis, Providencia rettgeri, and Morganella morganii, with MICgos of 0.78 ,ug/ml or less for each species. Its activity was roughly comparable to that of cefotaxime and slightly superior to that of ceftazidime. Citrobacter freundii, Enterobacter spp., and Serratia marcescens were less susceptible to DQ-2556 than were the other species of Enterobacteriaceae, but DQ-2556 inhibited these organisms at concentrations lower than those of ceftazidime and cefotaxime. Against P. aeruginosa, DQ-2556 inhibited 50 and 90% of the isolates at concentrations below 6.25 and 25 ,ug/ml, respectively. The activity of DQ-2556 was slightly inferior to that of ceftazidime. H. influenzae and N. gonorrhoeae were highly susceptible to DQ-2556, with MIC90s of 0.10 ,ug/ml. DQ-2556 displayed poor activity against methicillin-resistant staphylococci, Pseudomonas maltophilia, and Bacteroides fragilis (data not shown).
The activity of DQ-2556 against 50 isolates each of E. coli, K. pneumoniae, S. marcescens, and P. aeruginosa was not changed significantly at pHs of 6.0, 7.0, and 8.0 (data not shown). The MIC%0 of DQ-2556 for each species was the same or varied by one dilution when the five different media, i.e., Mueller-Hinton, nutrient, brain heart infusion, heart infusion, and tryptose blood agar, were used. When the inoculum was increased from 105 to 107 CFU, the MIC90s of DQ-2556 for E. coli and K. pneumoniae were not changed or doubled. For S. marcescens and P. aeruginosa, the increase in inoculum resulted in a fourfold or greater rise in the MIC90s of DQ-2556, whereas it resulted in a twofold rise for ceftazidime. The bactericidal activity of DQ-2556 was compared with that of ceftazidime (data not shown). The MBC90s of DQ-2556 against S. aureus, E. coli, S. marcescens, and P. aeruginosa were identical to or, at most, four times as high as the MIC90s, as were those of ceftazidime. However, DQ-2556 seemed to be less bactericidal than ceftazidime against P. aeruginosa. DQ-2556 is an interesting new cephalosporin with a wellbalanced antibacterial spectrum of activity. A major advantage of this compound was its high level of inhibitory and killing activity against members of the family Enterobacteriaceae, being roughly comparable to that of cefotaxime. DQ-2556 was the most active cephalosporin tested against S. marcescens, C. freundii, and Enterobacter spp. It also displayed good activity against P. aeruginosa, against which cefotaxime was much less active and ceftazidime was slightly more active. Thus, DQ-2556 has excellent activity against clinically important gram-negative pathogens. Furthermore, its antistaphylococcal activity was much better than that of ceftazidime, although it was barely active against methicillin-resistant staphylococci, as were the other cephalosporins tested. The pH and inoculum effects on the activity of DQ-2556 were not significant. These favorable in vitro results with DQ-2556 indicate that, depending on its pharmacokinetic and toxicological properties, it might prove to be a useful new broad-spectrum cephalosporin.
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